In vivo aggregation of β-amyloid peptide variants

Journal of Neurochemistry

Volumn 71, Issue 4, 1998, Pages 1616-1625

  Fay, David S ^a   Fluet, Amy ^a   Johnson, Carolyn J ^a   Link, Christopher D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Aggregation; Caenorhabditis elegans; Transgenic; Amyloid peptide; Amyloid peptide variant

Indexed keywords

ALANINE; AMYLOID BETA PROTEIN; CONGO RED; CYSTEINE; LEUCINE; METHIONINE; PROLINE; THIOFLAVINE; VALINE;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; GENETIC ENGINEERING; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN VARIANT; TRANSGENIC ANIMAL;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 0031712488     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71041616.x     Document Type: Article

References (47)

1. Batra J. K., FitzGerald D., Gately M., Chaudhary V. K., and Pastan I. (1990) Anti-Tact(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells J. Biol. Chem. 265, 15198-15202.
2. Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C. M., Kim G., Seekins S., Yager D., Slunt H. H., Wang R., Seeger M., Levey A. I., Gandy S. E., Copeland N. G., Jenkins N. A., Price D. L., Younkin S. G., and Sisodia S. S. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
3. Chen S. Y., Harding J. W., and Barnes C. D. (1996) Neuropathology of synthetic β-amyloid peptide analogs in vivo. Brain Res. 715, 44-50.
4. Choo L. P., Wetzel D. L., Halliday W. C., Jackson M., LeVine S. M., and Mantsch H. H. (1996) In situ characterization of β-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Biophys. J. 71, 1672-1679.
5. Esler W. P., Stimson E. R., Ghilardi J. R., Lu Y. A., Felix A. M., Vinters H. V., Mantyh P. W., Lee J. P., and Maggio J. E. (1996) Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry 35, 13914-13921.
6. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527.
7. Ghanta J., Shen C. L., Kiessling L. L., and Murphy R. M. (1996) A strategy for designing inhibitors of β-amyloid toxicity. J. Biol. Chem. 271, 29525-29528.
8. Gravina S. A., Ho L., Eckman C. B., Long K. E., Otvos L. Jr., Younkin L. H., Suzuki N., and Younkin S. G. (1995) Amyloid β protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A β 40 or A β 42(43). J. Biol. Chem. 270, 7013-7016.
9. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., and Butterfield D. A. (1994) A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 3270-3274.
10. Hilbich C., Kisters-Woike B., Reed J., Masters C. L., and Beyreuther K. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease β A4 peptides. J. Mol. Biol. 228, 460-473.
11. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
12. Iversen L. L., Mortishire-Smith R. J., Pollack S. J., and Shearman M. S. (1995) The toxicity in vitro of β-amyloid protein. Biochem. J. 311, 1-16.
13. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., and Akaike A. (1997) Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42, 159-163.
14. Kim K. S., Miller D. L., Sapienza V. J., Chen C.-M. J., Bai C., Grundke-Iqbal I., Currie J. R., and Wisniewski H. M. (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 2, 121-130.
15. Klafki H.-W., Wiltfang J., and Staufenbiel M. (1996) Electrophoretic separation of βA4 peptides. Anal. Biochem. 237, 24-29.
16. Kohno T., Kobayashi K., Maeda T., Sato K., and Takashima A. (1996) Three-dimensional structures of the amyloid β peptide (25-35) in membrane-mimicking environment. Biochemistry 35, 16094-16104.
17. Lemere C. A., Lopera F., Kosik K. S., Lendon C. L., Ossa J., Saido T. C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., Hincapie L., Arango J. C., Anthony D. C., Koo E. H., Goate A. M., Selkoe D. J., and Arango J. C. (1996) The E280A presenilin 1 Alzheimer mutation produces increased A β 42 deposition and severe cerebellar pathology. Nat. Med. 2, 1146-1150.
18. Link C. D. (1995) Expression of human β-amyloid peptide in transgenic Caenorhahditis elegans. Proc. Natl. Acad. Sci. USA 92, 9368-9372.
19. Lorenzo A. and Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
20. Mann D. M., Iwatsubo T., Nochlin D., Sumi S. M., Levy-Lahad E., and Bird T. D. (1997) Amyloid (Aβ) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann. Neurol. 41, 52-57.
21. Mello C. C., Kramer J. M., Stinchcomb D., and Ambros V. (1991) Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J. 10, 3959-3970.
22. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., et al. (1995) Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643-648.
23. Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207, 367-368.
24. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
25. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995) Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
26. Salomon A. R., Marcinowski K. J., Friedland R. P., and Zagorski M. G. (1996) Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 35, 13568-13578.
27. Seilheimer B., Bohrmann B., Bondolfi L., Muller F., Stuber D., and Dobeli H. (1997) The toxicity of the Alzheimer's β-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 119, 59-71.
28. Selkoe D. J. (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631.
29. Shen C. L. and Murphy R. M. (1995) Solvent effects on self-assembly of β-amyloid peptide. Biophys. J. 69, 640-651.
30. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham E. F., Wright S., Lieberburg I., Becker G. W., Brems D. N., and Li W. Y. (1994) Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45, 373-379.
31. Soto C. and Frangione B. (1995) Two conformational states of amyloid β-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci. Lett. 186, 115-118.
32. Soto C., Castano E. M., Frangione B., and Inestrosa N. C. (1995a) The alpha-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J. Biol. Chem. 270, 3063-3067.
33. Soto C., Castano E. M., Kumar R. A., Beavis R. C., and Frangione B. (1995b) Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure. Neurosci. Lett. 200, 105-108.
34. Soto C., Kindy M. S., Baumann M., and Frangione B. (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 226, 672-680.
35. Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K., Frank R. W., and Rosch P. (1995) Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233, 293-298.
36. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. Jr., Eckman C., Golde T. E., and Younkin S. G. (1994) An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP717) mutants. Science 264, 1336-1340.
37. Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., Hirai S., Furiya Y., Endoh R., and Mori H. (1997) Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Sci. 148, 41-45.
38. Terzi E., Holzemann G., and Seelig J. (1994) Reversible random coil-β-sheet transition of the Alzheimer β-amyloid fragment (25-35). Biochemistry 33, 1345-1350.
39. Terzi E., Holzemann G., and Seelig J. (1995) Self-association of β-amyloid peptide (1-40) in solution and binding to lipid membranes. J. Mol. Biol. 252, 633-642.
40. Tjernberg L. O., Naslund J., Lindqvist F., Johansson J., Karlstrom A. R., Thyberg J., Terenius L., and Nordstedt C. (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548.
41. Tomiyama T., Asano S., Suwa Y., Morita T., Kataoka K., Mori H., and Endo N. (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro. Biochem. Biophys. Res. Commun. 204, 76-83.
42. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., and Endo N. (1996) Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271, 6839-6844.
43. Ueda K., Fukui Y., and Kageyama H. (1994) Amyloid β protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid β protein. Brain Res. 639, 240-244.
44. Wetzel R., Wood S. J., Davis J. B., and Hurle M. R. (1994) Proline substitutions in β peptide fragments eliminate both fibril formation and cellular toxicity. Neurobiol. Aging 15 (Suppl. 1), S50.
45. Wiltfang J., Smirnov A., Schnierstein B., Kelemen G., Matthies U., Klafki H.-W., Staufenbiel M., Huther G., Ruther E., and Kornhuber J. (1997) Improved electrophoretic separation and immunoblotting of beta-amyloid (Aβ) peptides 1-40, 1-42, and 1-43. Electrophoresis 18, 527-532.
46. Wisniewski T., Ghiso J., and Frangione B. (1994) Alzheimer's disease and soluble A β. Neurobiol. Aging 15, 143-152.
47. Wood S. J., Wetzel R., Martin J. D., and Hurle M. R. (1995) Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4. Biochemistry 34, 724-730.